Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

66th Annual Scientific Sessions of the American College of Cardiology

17 March 2017
Washington DC, USA

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

The development of bococizumab, the third of the PCSK9 monoclonal antibodies, was discontinued by Pfizer in early November (1). Insights from a late breaker trial presentation provide some answers why this might be the case. SPIRE programme: lipid lowering trials The SPIRE program included 6…

read more »
SPIRE-2: Cardiovascular benefit in very high risk patients

SPIRE-2: Cardiovascular benefit in very high risk patients

Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…

read more »
A landmark day for PCSK9 inhibition

A landmark day for PCSK9 inhibition

What a landmark day for lipid lowering. All eyes were focused on FOURIER at the first of the late-breaking clinical trial sessions at ACC.2017. And the results didn’t disappoint. In patients with stable cardiovascular disease on maximally tolerated statin therapy, evolocumab treatment lowered LDL cholesterol…

read more »
PlayProf Raul Santos: SPIRE trials with bococizumab

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

read more »
FOURIER: a landmark trial

FOURIER: a landmark trial

Treatment with evolocumab on top of maximally tolerated statin led to significant reduction in the risk of major cardiovascular events, the primary study endpoint, by 15% (p<0.001), as well as a 20% reduction in the risk of the secondary ‘hard outcomes’ endpoint, a composite of…

read more »